YDESW News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

YD

Volume

11

Loading chart

YD

YDESWYD Bio Limited Warrants

YDESW

Pay with—

Available Balance0.00

YD

Mkt Cap

N/A

Volume

11

Next Earnings

N/A

Chart Earnings News About Insider Filings

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026YD Bio (Nasdaq: YDES), a biotechnology company focused on DNA methylation-based cancer detection and ophthalmologic innovations, announced H1 2026 results showing 315% revenue growth to $846.5 million and net income of $6.7 million. The profitability was primarily driven by a $9.8 million non-cash gain from warrant liability fair value changes. Excluding this adjustment, the company reported an operational net loss of $3.1 million. Revenue growth was fueled by large orders including a $327 million Fetroja order, though gross margins were pressured by lower-margin sales. The company is expanding its laboratory network, advancing exosome manufacturing, and pursuing strategic acquisitions while managing cash burn.GlobeNewswire Inc. · Aug 31, 2026

YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health InstituteYD Bio announced the publication of a peer-reviewed article in Nutrients journal co-authored with physicians from Taiwan's Chronic Disease Healthcare Association and Future Health Institute. The article explores how omega-3, vitamin D3, and vitamin K2 affect cardiovascular, neurological, and skeletal health. This publication expands YD Bio's physician-partnership initiative beyond product development into peer-reviewed research.GlobeNewswire Inc. · Aug 25, 2026

YD Bio Expands U.S. Laboratory Footprint to 46 States, Strengthening DNA-Methylation Early Cancer Detection OperationsYD Bio announced that its affiliate EG BioMed US obtained out-of-state clinical laboratory licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified laboratory's authorized operating footprint to 46 U.S. states plus Washington D.C. and Guam. The expansion supports the company's DNA methylation-based early cancer detection operations and broadens patient access to blood-based testing services for various cancers.GlobeNewswire Inc. · Jul 2, 2026

YD Bio Limited Reports Full Year 2025 Financial ResultsYD Bio (Nasdaq: YDES) announced full-year 2025 financial results showing 17% net revenue increase to $596.8 million, driven by pharmaceutical sales growth and new product launches. However, the company reported a net loss of $8.3 million compared to $1.4 million in 2024, primarily due to a $3.2 million change in warrant liabilities and increased operating expenses from business expansion. The company ended 2025 with $6.0 million in cash and outlined 2026 strategic priorities including FDA submissions for its Limbal Stem Cell platform and pancreatic cancer detection program, along with planned M&A activities.GlobeNewswire Inc. · Apr 30, 2026

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations CenterYD Bio Limited plans to establish a new U.S. operations center in California to accelerate clinical development, regulatory engagement, and commercial access for cancer diagnostics and exosome-based therapeutics.GlobeNewswire Inc. · Dec 16, 2025

to start trading

YD

YDESWYD Bio Limited Warrants

YDESW

Pay with—

Available Balance0.00

Your PositionYou don't own any YDESW yet.

Related Tickers

Earnings